Comparison of Single Versus Repeat Doses of AM-101 in the Treatment of Acute Inner Ear Tinnitus
Phase of Trial: Phase II
Latest Information Update: 20 Apr 2015
At a glance
- Drugs Esketamine (Primary)
- Indications Tinnitus
- Focus Therapeutic Use
- Acronyms TACTT1
- Sponsors Auris Medical
- 20 Apr 2015 According to an Auris Medical media release, results from this trial were published in Audiology and Neurotology journal.
- 20 Apr 2015 Primary endpoint 'The change in tinnitus loudness by magnitude estimation from Baseline to 90 days following the last injection' has not been met, according to an Auris Medical media release.
- 18 Sep 2014 New trial record